Cytovance Biologics Inc.
This article was originally published in Start Up
Executive Summary
Cytovance intends to make the outsourcing of clinical-stage protein manufacturing easily accessible to small firms, so they don't have to invest their precious cash in this sort of infrastructure. The worldwide scarcity of biological manufacturing capacity is of growing concern to development-stage companies all too aware of the misfortune that Immunex Corp. suffered through inability to adequately meet market demand for its rheumatoid arthritis drug etanercept (Enbrel).